In this collaborative effort with GSK, Cellzome, UCLA, The Leloir Institute, and the National University of Córdobawe performed a synthetic lethality screen with natural products from Argentina, which allowed us to identify dCK as a novel target in BRCA2-deficient cancers.

The trapping of Poly-ADP-ribose polymerase (PARP) on DNA caused by PARP inhibitors (PARPi) triggers acute DNA replication stress and synthetic lethality (SL) in BRCA2-deficient cells. Hence, DNA damage is accepted as a prerequisite for SL in BRCA2-deficient cells. In contrast, here we show that inhibiting ROCK in BRCA2-deficient cells triggers SL independently from acute replication stress.

In this work we developed a flow-cytometry-based co-culture screening technology for drug discovery, and we used to explore a public kinase inhibitor set.

In this work we used our flow-cytometry-based co-culture screening technology to screen a collection of 50 plants species from South America in a wide dose-response scheme.

In this work we performed In Silico screenings to identifty phosphor regulatory sites of the EMT factor ZEB1 and validated PKCα as a novel partner capable of modulating its premetastatic properties.

In this work we perform studies of correlations of drug sensitivity of a cell line database with transcriptomic classes of cancer cells derived from a commercial breast cancer signature.